Resolutions from Annual General Meeting, 11 June 2020

Lipidor AB held its Annual General Meeting (“AGM”) today, on the 11 June 2020, in Solna. The AGM elected the Chairman-elect of the Board, Fredrik Sjövall, as Chairman of the meeting. The AGM resolved in all proposed items in accordance with the proposals previously announced by the Board of Directors or the shareholders. A summary of the most important resolutions follows below.

Dividend
The AGM resolved that no dividend is to be paid for the financial year of 2019.

Discharge from liability
The Board of Directors and the CEO were discharged from liability for the financial year 2019.

Board of Directors
Fredrik Sjövall, Ola Flink and Gunilla Lundmark was re-elected as members of the board and Otto Skolling and Denis Angioletti were elected as new members of the board. It was noted that Per Nilsson and Gabriel Haering had declined to be re-elected. Fredrik Sjövall was elected as new chairman of the board. It was also resolved that remuneration to the board of directors will be SEK 200,000 for the Chairman of the Board and SEK 100,000 to every other independent board member. PwC was re-elected as auditor and the authorised public accountant Magnus Lagerberg continues as principal auditor. It was resolved that remuneration to the auditor will be according to approved invoicing.

Authorisation for the Board of Directors to resolve on new issues of shares, share warrants or convertibles
The AGM resolved to authorise the Board of Directors to decide on issue of new shares, warrants or convertibles, on one or several occasions during the time up to the next AGM, with or without preferential rights for the shareholders. Issues resolved upon pursuant to the authorisation may not increase the number of shares by more than 20 percent of the number of the outstanding shares as per the date of the notice convening the AGM.

Other resolutions
The AGM resolved on instructions for a Nomination Committee.

For more information, please contact

Ola Holmlund, CEO
Phone: +46 72 50 70 369
E-mail: ola.holmlund@lipidor.se

Certified Adviser

Corpura Fondkommission AB
Telephone: +46 76 85 32 822
E-mail: ca@corpura.se

About Lipidor

Lipidor AB (www.lipidor.se) is a Swedish, Stockholm-based research and development company with a pipeline of pharmaceutical development projects in preclinical and clinical phases. The Company develops topical medical products for the treatment of diseases such as psoriasis, bacterial skin infections and atopic dermatitis by reformulation of proven pharmaceutical substances.

Tags: